BACKGROUND: There are currently three main treatment strategies for onychomycosis: topical, oral and combination. Amorolfine nail lacquer appears to be the most effective form of topical monotherapy. However, the best mycological and clinical cure rates are obtained with combination therapy. Combination therapy increases antifungal spectrum, fungicidal activity and safety. New antifungals (triazoles and echinocandins) were recently developed, enabling new protocols. OBJECTIVES: To review available therapies. To design an algorithm for the management of onychomycoses in daily practice. RESULTS: Therapeutic choice should be based on numerous factors including patient's age and health, aetiology, extent of involvement and clinical form. The consensus was that topical monotherapy is recommended when < 50% of the nail is affected without matrix area involvement. Oral monotherapy or combination therapy is indicated when > 50% of the nail, including the matrix area, is involved. Topical treatments should not be used alone when topical drug transport is suboptimal (i.e. when dermatophytoma, onycholysis or spikes are present). Chemical or mechanical removal should also be considered whenever applicable (interruption of drug transport). CONCLUSION: In conclusion, treatment decision-making tools (e.g. an illustrated booklet or CD-ROM presenting each type of onychomycosis and criteria to be considered before selecting treatment regimen) would be valuable supports for the successful treatment of onychomycoses.
BACKGROUND: There are currently three main treatment strategies for onychomycosis: topical, oral and combination. Amorolfine nail lacquer appears to be the most effective form of topical monotherapy. However, the best mycological and clinical cure rates are obtained with combination therapy. Combination therapy increases antifungal spectrum, fungicidal activity and safety. New antifungals (triazoles and echinocandins) were recently developed, enabling new protocols. OBJECTIVES: To review available therapies. To design an algorithm for the management of onychomycoses in daily practice. RESULTS: Therapeutic choice should be based on numerous factors including patient's age and health, aetiology, extent of involvement and clinical form. The consensus was that topical monotherapy is recommended when < 50% of the nail is affected without matrix area involvement. Oral monotherapy or combination therapy is indicated when > 50% of the nail, including the matrix area, is involved. Topical treatments should not be used alone when topical drug transport is suboptimal (i.e. when dermatophytoma, onycholysis or spikes are present). Chemical or mechanical removal should also be considered whenever applicable (interruption of drug transport). CONCLUSION: In conclusion, treatment decision-making tools (e.g. an illustrated booklet or CD-ROM presenting each type of onychomycosis and criteria to be considered before selecting treatment regimen) would be valuable supports for the successful treatment of onychomycoses.
Authors: Maria Fernanda Reis Gavazzoni Dias; Maria Victória Pinto Quaresma-Santos; Fred Bernardes-Filho; Adriana Gutstein da Fonseca Amorim; Regina Casz Schechtman; David Rubem Azulay Journal: An Bras Dermatol Date: 2013 Sep-Oct Impact factor: 1.896
Authors: Nilton Di Chiacchio; Gustavo de Sá Menezes Carvalho; Nilton Gioia Di Chiacchio; Cristina Diniz Borges Figueira de Mello; John Verrinder Veasey Journal: Skin Appendage Disord Date: 2021-05-25
Authors: C Savin; S Huck; C Rolland; M Benderdouche; O Faure; G Noacco; J Menotti; E Candolfi; H Pelloux; R Grillot; S Coupe; F Derouin Journal: J Clin Microbiol Date: 2007-02-07 Impact factor: 5.948
Authors: Katarzyna Tabara; Anna E Szewczyk; Wojciech Bienias; Agnieszka Wojciechowska; Marta Pastuszka; Magdalena Oszukowska; Andrzej Kaszuba Journal: Postepy Dermatol Alergol Date: 2015-02-03 Impact factor: 1.837
Authors: Maria Fernanda Reis Gavazzoni Dias; Fred Bernardes-Filho; Maria Victória Pinto Quaresma-Santos; Adriana Gutstein da Fonseca Amorim; Regina Casz Schechtman; David Rubem Azulay Journal: An Bras Dermatol Date: 2013 Nov-Dec Impact factor: 1.896